Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (Phase I/IIa) The BELI(E)VE-Trial

NCT05853965 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT05853965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05853965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (Phase I/IIa) The BELI(E)VE-Trial
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 28, 2023
Completion date
December 31, 2028
Enrollment
45 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma in relapse